SG11201505858VA - A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease - Google Patents
A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious diseaseInfo
- Publication number
- SG11201505858VA SG11201505858VA SG11201505858VA SG11201505858VA SG11201505858VA SG 11201505858V A SG11201505858V A SG 11201505858VA SG 11201505858V A SG11201505858V A SG 11201505858VA SG 11201505858V A SG11201505858V A SG 11201505858VA SG 11201505858V A SG11201505858V A SG 11201505858VA
- Authority
- SG
- Singapore
- Prior art keywords
- infectious disease
- cell therapy
- chimeric receptor
- against cancer
- therapy against
- Prior art date
Links
- 208000035473 Communicable disease Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002659 cell therapy Methods 0.000 title 1
- 108700010039 chimeric receptor Proteins 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361757481P | 2013-01-28 | 2013-01-28 | |
PCT/US2014/013292 WO2014117121A1 (en) | 2013-01-28 | 2014-01-28 | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201505858VA true SG11201505858VA (en) | 2015-09-29 |
Family
ID=51228124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201505858VA SG11201505858VA (en) | 2013-01-28 | 2014-01-28 | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
Country Status (4)
Country | Link |
---|---|
US (8) | US9511092B2 (en) |
EP (1) | EP2948544A4 (en) |
SG (1) | SG11201505858VA (en) |
WO (1) | WO2014117121A1 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10332332B2 (en) | 2007-12-21 | 2019-06-25 | Cfph, Llc | System and method for slot machine game associated with financial market indicators |
US8758108B2 (en) | 2007-12-21 | 2014-06-24 | Cfph, Llc | System and method for slot machine game associated with market line wagers |
US11257330B2 (en) | 2008-02-15 | 2022-02-22 | Cfph, Llc | System and method for providing a baccarat game based on financial market indicators |
WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
CA2948462A1 (en) | 2014-05-15 | 2015-11-19 | National University Of Singapore | Modified natural killer cells and uses thereof |
GB201501175D0 (en) | 2015-01-23 | 2015-03-11 | Univ Oslo Hf | A universal T-cell for personalised medicine |
US10640570B2 (en) * | 2015-01-29 | 2020-05-05 | Regents Of The University Of Minnesota | Chimeric antigen receptors, compositions, and methods |
US10744157B2 (en) * | 2015-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using |
WO2017004252A1 (en) * | 2015-06-30 | 2017-01-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with mhc chimeric receptors and methods of use in immunotherapy |
US10875919B2 (en) | 2016-04-26 | 2020-12-29 | Alector Llc | Chimeric receptors and methods of use thereof |
US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
WO2018165913A1 (en) * | 2017-03-15 | 2018-09-20 | 南京凯地生物科技有限公司 | Specific chimeric antigen receptor targeting nkg2dl and car-t cell thereof and use thereof |
RU2019128544A (en) | 2017-03-27 | 2021-04-28 | Нэшнл Юниверсити Оф Сингапур | LINE OF STIMULATING CELLS FOR EX VIVO REPRODUCTION AND ACTIVATION OF NATURAL KILLER CELLS |
CN117384929A (en) * | 2017-03-27 | 2024-01-12 | 新加坡国立大学 | Polynucleotide encoding chimeric receptor expressed by cell |
EP3612210A4 (en) | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
EP3720951A1 (en) * | 2017-12-05 | 2020-10-14 | Celyad S.A. | Compositions and methods for improving persistence of cells for adoptive transfer |
CN112218943A (en) | 2017-12-05 | 2021-01-12 | 塞利亚德股份公司 | Killing agents to reduce immune cells expressing NKG 2D-based receptors |
WO2019127215A1 (en) * | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof |
TW201940182A (en) | 2018-01-22 | 2019-10-16 | 美商安德賽特公司 | Methods of use for CAR T cells |
CA3089170A1 (en) * | 2018-02-09 | 2019-08-15 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
JP2021512614A (en) * | 2018-02-09 | 2021-05-20 | ナショナル ユニヴァーシティー オブ シンガポール | Adhesive receptor constructs and their use in natural killer cell immunotherapy |
US20210309713A1 (en) * | 2018-04-04 | 2021-10-07 | Daren Biotech Limited | Chimeric Antigen Receptor and Method for Treating Cancers |
WO2019195541A1 (en) * | 2018-04-06 | 2019-10-10 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Nkg2d chimeric antigen receptors |
WO2020005837A1 (en) * | 2018-06-25 | 2020-01-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer |
EP3850004A4 (en) * | 2018-09-13 | 2022-09-07 | Nkarta, Inc. | Natural killer cell compositions and immunotherapy methods for treating tumors |
JP2022512922A (en) * | 2018-11-06 | 2022-02-07 | ワシントン・ユニバーシティ | Chimeric antigen receptor memory-like (CARML) NK cells and their production and usage |
WO2020160419A1 (en) * | 2019-02-01 | 2020-08-06 | The Trustees Of Dartmouth College | Signaling platforms for chimeric antigen receptor t cells |
CN111544585A (en) * | 2019-02-11 | 2020-08-18 | 北京卡替医疗技术有限公司 | Adjuvant capable of boosting immune cells to expand in vivo |
EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
US20200308248A1 (en) * | 2019-03-26 | 2020-10-01 | ST Phi Therapeutics | Chimeric Natural Killer Cell Receptors and Method of Using Thereof |
CN111363046A (en) * | 2020-03-11 | 2020-07-03 | 深圳宾德生物技术有限公司 | Chimeric antigen receptor targeting NKG2D, chimeric antigen receptor T cell, and preparation method and application thereof |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
AR124414A1 (en) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | CHIMERIC ANTIGEN RECEPTOR SYSTEM WITH ADAPTABLE RECEPTOR SPECIFICITY |
GB202110363D0 (en) | 2021-07-19 | 2021-09-01 | Celyad S A | NKG2D CAR cells expressing IL-18 for adoptive cell therapy |
WO2023086642A2 (en) * | 2021-11-15 | 2023-05-19 | City Of Hope | Engineering or inducing pdgf and/or pdgfr signaling to enhance nk cell therapy |
CN116179495A (en) * | 2022-11-28 | 2023-05-30 | 上海恩凯细胞技术有限公司 | Transgenic immune cells and uses thereof |
KR20240111378A (en) | 2023-01-09 | 2024-07-17 | 주식회사 셀젠텍 | NKG2D Chimeric Receptor, Transformed Cell Expressing the Same and Its Use for Anti-Cancer |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19520729A1 (en) | 1995-06-07 | 1996-12-12 | Orpegen Pharma Gmbh | Test system for recording the activity of NK cells |
EP1003861B1 (en) | 1997-08-01 | 2006-10-04 | Schering Corporation | Mammalian cell membrane proteins; related reagents |
DE69916581T2 (en) | 1998-02-02 | 2004-09-16 | The Johns Hopkins University School Of Medicine | A UNIVERSAL IMMUNO-MODULATORY CYTOKIN-EXPRESSING CELL LINE IN WAITING. CORRESPONDING COMPOSITIONS AND METHODS OF THEIR PRODUCTION AND USE |
DE19813759C1 (en) | 1998-03-27 | 1999-07-15 | Gsf Forschungszentrum Umwelt | Inducing a natural killer cell immune response ex vivo |
AU7954500A (en) | 1999-10-21 | 2001-04-30 | Yuji Ohkubo | Method of in vitro culture of lymphocytes and gene therapy compositions |
JP3619853B2 (en) | 1999-11-26 | 2005-02-16 | 独立行政法人理化学研究所 | Method of growing natural killer cells |
JP2002045174A (en) | 2000-07-31 | 2002-02-12 | Inst Of Physical & Chemical Res | Method for proliferating natural killer cell |
EP1578923A4 (en) * | 2002-04-22 | 2009-01-21 | Hutchinson Fred Cancer Res | Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
AU2003270823A1 (en) | 2002-09-19 | 2004-04-08 | Johns Hopkins University School Of Medicine | Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
WO2006036445A2 (en) * | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Chimeric nk receptor and methods for treating cancer |
GB0426903D0 (en) | 2004-12-08 | 2005-01-12 | Alexis Biotech Ltd | Complexes and methods |
JP2009513608A (en) | 2005-10-28 | 2009-04-02 | ノボ・ノルデイスク・エー/エス | Fusion protein that binds effector lymphocytes to target cells |
DK2537416T3 (en) | 2007-03-30 | 2015-01-05 | Sloan Kettering Inst Cancer | Constitutive expression of costimulatory ligands ON adoptively transferred T-LYMPHOCYTES |
WO2009117566A1 (en) | 2008-03-21 | 2009-09-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chemokine gene-modified cells for cancer immunotherapy |
WO2016149264A1 (en) | 2015-03-18 | 2016-09-22 | The Johns Hopkins University | Compositions and methods for sensitizing cells to trail-induced apoptosis |
CN102428173B (en) | 2009-03-26 | 2014-07-30 | 细胞维护北欧制药公司 | Expansion of NK cells |
WO2011053321A1 (en) | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells for treatment of multiple myeloma |
WO2011053322A1 (en) | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
JP5916718B2 (en) * | 2010-06-04 | 2016-05-11 | ビオメリューBiomerieux | Method and kit for determining prognosis of colorectal cancer |
WO2012002040A1 (en) | 2010-07-01 | 2012-01-05 | Semiconductor Energy Laboratory Co., Ltd. | Driving method of liquid crystal display device |
BR112013000822B1 (en) | 2010-07-13 | 2021-02-23 | Anthrogenesis Corporation | TWO-STEP IN VITRO METHOD FOR THE PRODUCTION OF A POPULATION OF ACTIVATED NATURAL EXTERMINATOR (NK) PEOPLE |
EP2614151B1 (en) | 2010-09-08 | 2019-07-24 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
ES2754394T3 (en) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Chimeric antigen receptors with an optimized hinge region |
CN106963947A (en) | 2010-11-22 | 2017-07-21 | 伊纳特医药股份有限公司 | NK cells adjustment for the treatment of and the method for treating Hematological Malignancies |
AU2012308205A1 (en) | 2011-09-16 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | RNA engineered T cells for the treatment of cancer |
WO2013126720A2 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing |
WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
SG11201408697QA (en) | 2012-06-28 | 2015-02-27 | Univ Central Florida Res Found | Methods and compositions for natural killer cells |
EP2872617A4 (en) | 2012-07-13 | 2015-12-09 | Univ Pennsylvania | Epitope spreading associated with car t-cells |
AR092745A1 (en) | 2012-10-01 | 2015-04-29 | Univ Pennsylvania | COMPOSITIONS THAT INCLUDE AN ANTI-FAP UNION DOMAIN AND METHODS TO MAKE WHITE IN STROMAL CELLS FOR THE TREATMENT OF CANCER |
EP2903637B1 (en) | 2012-10-02 | 2019-06-12 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
US10786532B2 (en) | 2012-10-02 | 2020-09-29 | Versiti Blood Research Institute Foundation, Inc. | Method of providing cellular therapy using modified natural killer cells or T lymphocytes |
US20150329640A1 (en) | 2012-12-20 | 2015-11-19 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
PT3613439T (en) | 2013-02-15 | 2021-05-12 | Univ California | Chimeric antigen receptor and methods of use thereof |
MY175869A (en) | 2013-02-26 | 2020-07-14 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
CA2904369A1 (en) | 2013-03-07 | 2014-09-12 | Baylor College Of Medicine | Targeting cd138 in cancer |
JP2016513458A (en) | 2013-03-10 | 2016-05-16 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | Chemotherapy resistant immune cells |
EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
MY195733A (en) | 2013-03-15 | 2023-02-08 | Memorial Sloan Kettering Cancer Center | Compositions and Methods for Immunotherapy |
EP3470423B1 (en) | 2013-04-17 | 2021-10-06 | Baylor College of Medicine | Immunosuppressive tgf-beta signal converter |
EP3974520A1 (en) | 2013-05-14 | 2022-03-30 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
EP3008173B1 (en) | 2013-06-10 | 2021-09-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for reducing immunosupression by tumor cells |
KR102245536B1 (en) | 2013-07-16 | 2021-04-28 | 아크조노벨코팅스인터내셔널비.브이. | Intumescent composition |
WO2015042661A2 (en) | 2013-09-24 | 2015-04-02 | Vayeron Pty Ltd | An idler, a method for monitoring a plurality of idlers, and a conveyor system |
JP6417413B2 (en) | 2013-10-17 | 2018-11-07 | ナショナル ユニヴァーシティー オブ シンガポール | Chimeric receptors induce antibody-dependent cytotoxicity against a variety of tumors |
CA2929087A1 (en) | 2013-10-31 | 2015-05-07 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
EP3071223B1 (en) | 2013-11-21 | 2021-01-13 | UCL Business Ltd | Cell |
US10239948B2 (en) | 2013-12-20 | 2019-03-26 | Cellectis | Method of engineering multi-input signal sensitive T cell for immunotherapy |
SI3083671T1 (en) | 2013-12-20 | 2021-02-26 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
CN113307880A (en) | 2014-01-13 | 2021-08-27 | 希望之城公司 | Chimeric Antigen Receptors (CARs) having mutations in the Fc spacer region and methods of use thereof |
CN106414723A (en) | 2014-02-10 | 2017-02-15 | 纳维基因股份有限公司 | Cell modulation nanocomposition, and methods of use |
KR102375998B1 (en) | 2014-02-14 | 2022-03-21 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Chimeric antigen receptors and methods of making |
US20170081411A1 (en) | 2014-03-15 | 2017-03-23 | Novartis Ag | Regulatable chimeric antigen receptor |
GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
WO2015154012A1 (en) | 2014-04-03 | 2015-10-08 | Memorial Sloan-Kettering Cancer Center | Clonogenic natural killer (nk) cell populations and methods of producing and using such populations |
KR102021982B1 (en) | 2014-04-25 | 2019-09-18 | 블루버드 바이오, 인코포레이티드. | Mnd promoter chimeric antigen receptors |
EP3169773B1 (en) | 2014-07-15 | 2023-07-12 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
US10851149B2 (en) | 2014-08-14 | 2020-12-01 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using GFR α-4 chimeric antigen receptor |
WO2016033331A1 (en) | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
CN106687584B (en) | 2014-09-04 | 2021-08-13 | 干细胞技术公司 | Soluble antibody complexes for T cell or NK cell activation and expansion |
CA2972714A1 (en) | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
UA123764C2 (en) | 2014-09-15 | 2021-06-02 | МОЛМЕД СпА | Chimeric antigen receptors |
EP3193894A1 (en) | 2014-09-16 | 2017-07-26 | Fundación Pública Andaluza Progreso Y Salud | Use of cord blood plasma to treat nk cell-mediated diseases and ifn- mediated diseases |
MA41538A (en) | 2014-10-17 | 2017-12-26 | Baylor College Medicine | BIPARTITE AND TRIPARTITE IMMUNE CELLS OF SIGNALING |
BR112017008696A2 (en) | 2014-10-27 | 2017-12-26 | Univ Central Florida Res Found Inc | methods and compositions for natural killer cells |
WO2016073755A2 (en) | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
IL292450A (en) | 2014-11-05 | 2022-06-01 | Juno Therapeutics Inc | Methods for transduction and cell processing |
ES2806126T3 (en) | 2014-11-05 | 2021-02-16 | Univ Texas | Chimeric antigen receptors (CARs) selectively target protein complexes |
EP3233900A2 (en) | 2014-12-19 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptors and methods of use thereof |
JP2018502115A (en) | 2014-12-31 | 2018-01-25 | アントフロゲネシス コーポレーション | Natural killer cells and uses thereof |
US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
MA41433A (en) | 2015-01-26 | 2017-12-05 | Baylor College Medicine | UNIVERSAL IMMUNE CELLS FOR ANTI-CANCER IMMUNOTHERAPY |
US10640570B2 (en) | 2015-01-29 | 2020-05-05 | Regents Of The University Of Minnesota | Chimeric antigen receptors, compositions, and methods |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
US20190024065A1 (en) | 2015-02-06 | 2019-01-24 | Cellectis | Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles |
WO2016141357A1 (en) | 2015-03-05 | 2016-09-09 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
US9777064B2 (en) | 2015-03-17 | 2017-10-03 | Chimera Bioengineering, Inc. | Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof |
WO2016154055A1 (en) | 2015-03-20 | 2016-09-29 | Bluebird Bio, Inc. | Vector formulations |
GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
US20180092968A1 (en) | 2015-04-23 | 2018-04-05 | The Trustees Of The University Of Pennsylvania | Compositions to disrupt protein kinase a anchoring and uses thereof |
GB201507119D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
GB201507111D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
GB201507115D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
WO2016174652A1 (en) | 2015-04-30 | 2016-11-03 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
WO2016191567A1 (en) | 2015-05-26 | 2016-12-01 | Memorial Sloan-Kettering Cancer Center | System, method and computer-accessible medium for texture analysis of hepatopancreatobiliary diseases |
CN107847583A (en) | 2015-05-28 | 2018-03-27 | 阿尔莫生物科技股份有限公司 | PEGylated Interleukin 10 for treating cancer |
BR122023022076A2 (en) | 2015-05-28 | 2024-01-16 | Kite Pharma, Inc. | PRECONDITIONING AGENTS, THEIR USES AND METHODS FOR IDENTIFYING A DOSE OF ONE OR MORE PRECONDITIONING AGENTS AND FOR VERIFYING THEIR EFFECTIVENESS |
AU2016271147B2 (en) | 2015-05-29 | 2022-09-08 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
WO2016197108A1 (en) | 2015-06-05 | 2016-12-08 | Board Of Regents, The University Of Texas System | Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type |
CN107849112B (en) | 2015-06-25 | 2022-04-01 | 美商生物细胞基因治疗有限公司 | Chimeric Antigen Receptors (CAR), compositions and methods of use thereof |
CN108137707A (en) | 2015-06-29 | 2018-06-08 | 约翰霍普金斯大学 | Immunologic test point Chimerical receptor therapy |
MA42895A (en) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | MODIFIED CELLS FOR ADOPTIVE CELL THERAPY |
EP3328994A4 (en) | 2015-07-31 | 2019-04-17 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting cd56 and uses thereof |
GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
GB201514874D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Cell |
AU2016313082B2 (en) | 2015-08-24 | 2022-03-31 | Cellectis | Chimeric antigen receptors with integrated controllable functions |
CN106519037B (en) | 2015-09-11 | 2019-07-23 | 科济生物医药(上海)有限公司 | Activable Chimerical receptor |
KR20180051625A (en) | 2015-09-17 | 2018-05-16 | 노파르티스 아게 | CAR T cell therapy with enhanced efficacy |
WO2017058752A1 (en) | 2015-09-28 | 2017-04-06 | Trustees Of Dartmouth College | Chimeric antigen receptor anti-inflammatory cells and methods of use |
WO2017058753A1 (en) | 2015-09-28 | 2017-04-06 | Trustees Of Dartmouth College | Chimeric antigen receptor, regulatory cells and methods of use |
MA44314A (en) | 2015-11-05 | 2018-09-12 | Juno Therapeutics Inc | CHEMERICAL RECEPTORS CONTAINING TRAF-INDUCING DOMAINS, AND ASSOCIATED COMPOSITIONS AND METHODS |
AU2017210031C1 (en) | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
-
2014
- 2014-01-28 WO PCT/US2014/013292 patent/WO2014117121A1/en active Application Filing
- 2014-01-28 US US14/764,070 patent/US9511092B2/en active Active
- 2014-01-28 SG SG11201505858VA patent/SG11201505858VA/en unknown
- 2014-01-28 EP EP14743792.5A patent/EP2948544A4/en not_active Withdrawn
-
2016
- 2016-10-28 US US15/337,854 patent/US10538739B2/en active Active
-
2017
- 2017-12-28 US US15/857,268 patent/US10829737B2/en active Active
- 2017-12-28 US US15/857,166 patent/US10774309B2/en active Active
- 2017-12-28 US US15/857,147 patent/US10801012B2/en active Active
- 2017-12-28 US US15/857,315 patent/US10836999B2/en active Active
-
2020
- 2020-10-09 US US17/067,016 patent/US11873512B2/en active Active
-
2023
- 2023-11-16 US US18/511,513 patent/US20240191196A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170107491A1 (en) | 2017-04-20 |
US10538739B2 (en) | 2020-01-21 |
US10774309B2 (en) | 2020-09-15 |
US10801012B2 (en) | 2020-10-13 |
US11873512B2 (en) | 2024-01-16 |
US20180135016A1 (en) | 2018-05-17 |
US20210115404A1 (en) | 2021-04-22 |
EP2948544A4 (en) | 2016-08-03 |
US10829737B2 (en) | 2020-11-10 |
EP2948544A1 (en) | 2015-12-02 |
US10836999B2 (en) | 2020-11-17 |
US20240191196A1 (en) | 2024-06-13 |
US20180135015A1 (en) | 2018-05-17 |
US9511092B2 (en) | 2016-12-06 |
US20160000828A1 (en) | 2016-01-07 |
US20180135014A1 (en) | 2018-05-17 |
WO2014117121A1 (en) | 2014-07-31 |
US20180135013A1 (en) | 2018-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201505858VA (en) | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease | |
IL282741B1 (en) | Tazemetostat in combination with a standard care agent for use in the treatment of cancer | |
HK1214661A1 (en) | Facilitating transactions with a user account using a wireless device | |
SG10202004535PA (en) | Enhanced adoptive cell therapy | |
EP3043819A4 (en) | Anti-vstm5 antibodies and the use thereof in therapy and diagnosis | |
IL246083A0 (en) | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy | |
EP2957270A4 (en) | Disposable urine-absorption pad with bedsore-inhibition function | |
GB201318977D0 (en) | Reactor and alkylation process using the reactor | |
PL2831055T3 (en) | Polymerizable alkylidene-1,3-dioxolan-2-ones and use thereof | |
EP2784843A4 (en) | Slurry with improved dispersibility and use therefor | |
HK1216980A1 (en) | Improvements in wheeled suitcases | |
EP2608630A4 (en) | Planar heating body | |
HK1217964A1 (en) | Cushion-like shaped body and use thereof | |
EP3038182A4 (en) | Battery pack having curved surface structure | |
EP2872973A4 (en) | Improvements in devices for use with computers | |
EP2935215A4 (en) | Radiosensitizer compounds for use in combination with radiation | |
HK1211458A1 (en) | Disposable body warmer | |
EP2808175A4 (en) | Erasing implement and writing implement provided with erasing implement | |
IL238453A0 (en) | Trans-clomiphene for use in cancer therapy | |
EP2836838A4 (en) | Methods for determining a breast cancer-associated disease state and arrays for use in the methods | |
GB201310921D0 (en) | Peptide-resin conjugate and use thereof | |
GB201221227D0 (en) | Carbon materials and their use | |
GB201305940D0 (en) | Methods and arrays for use in the same | |
PL2978521T3 (en) | Inclined baseplate in dehydrogenation reactor | |
GB2520471B (en) | Anatomically conforming vaginal insert with cover |